Terns Pharmaceuticals, Inc. TERN 深 滬
等待開盤 01-09 09:30:00 美东时间
37.77
-2.230
-5.57%
華盛通- 最 高40.39
- 今 開39.94
- 成交量 274.20万股
- 最 低 37.1653
- 昨 收 40.00
- 總市值 32.99亿
- 52周最高 48.26
- 市盈率 靜 --
- 換手率 3.14%
- 52周最低 1.865
- 委 比 57.73%
- 總股本 8733.78万
- 歷史最高 48.26
- 量 比 1.30
- 振 幅 8.06%
- 歷史最低 1.45
- 每 手 1
- 風險率 11.33%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
Terns Pharmaceuticals granted equity inducement awards to two new employees under the 2022 Employment Inducement Award Plan. The awards, totaling options for 312,000 shares of common stock with a $40.40 exercise price, vest over four years. The stock options were approved by the Compensation Committee and comply with Nasdaq Listing Rule 5635(c)(4). Terns is a clinical-stage oncology company focused on innovative cancer treatments.
01-02 21:05
美股周涨跌榜 | “减肥神药”临床数据引爆！WaVe生命科学周涨121%；太空概念股Planet Labs周涨42.8%
“减肥神药”临床数据引爆！WaVe生命科学周涨121%；福尼克斯周内飙升50%，创历史新高；SpaceX上市传闻引爆市场，太空概念股Planet Labs周涨42.8%>>
2025-12-13 10:07
美股大行评级 | 绩后分化！甲骨文遭14家大行集体下调目标价；新思科技、Planet获多家机构上调目标价！
今日重点评级关注：HC Wainwright & Co.：维持Moleculin Biotech"买入"评级，目标价从4美元升至22美元；HC Wainwright & Co.：上调Soluna Holdings评级至"买入"，目标价5美元
2025-12-12 10:24
Terns Pharmaceutical prices stock at $40 per share
Terns Pharmaceuticals (TERN) priced an upsized underwritten public offering of 16.25M shares at a public offering price of $40.00 per share. The gross proceeds from the offering are expected to be $65...
2025-12-10 15:20
美股大行评级 | 花旗上调苹果目标价升至330美元；GPCR、KYMR、MAMA、TERN、WVE等获多家机构上调目标价
今日重点评级关注：Chardan Capital：维持Senti Biosciences"买入"评级，目标价从12美元升至13美元；Guggenheim：维持Praxis Precision Medicine"买入"评级，目标价从540美元升至760美元
2025-12-10 10:33
Terns Announces Pricing of Upsized $650 Million Public Offering
Terns Pharmaceuticals announced the pricing of its upsized underwritten public offering of 16,250,000 shares of common stock at $40.00 per share, raising $650 million in gross proceeds. The company granted underwriters a 30-day option to purchase up to an additional 2,437,500 shares. Proceeds will be used for research, clinical trials, and development of key product candidates, including TERN-701. Jefferies, TD Cowen, and Leerink Partners are lea...
2025-12-10 04:30
Terns Pharmaceuticals proposes $400M equity offering
Terns Pharmaceuticals (TERN) has launched a proposed $400M public offering of common stock and pre-funded warrants. The company also plans to give underwriters a 30-day option to buy up to an addition...
2025-12-09 19:37
美股牛股 | “减肥神药”临床数据引爆！WaVe生命科学涨超147%，硕迪生物涨超102%；Confluent涨超29%
“减肥神药”临床数据引爆！WaVe生命科学涨超147%，硕迪生物涨超102%；Confluent涨超29%，IBM拟110亿美元收购该公司>>
2025-12-09 17:40
Terns Announces Proposed Public Offering
Terns Pharmaceuticals has announced a proposed underwritten public offering of $400 million in shares of its common stock and pre-funded warrants. The underwriters have an option to purchase an additional $60 million. The company plans to use the proceeds for research, clinical trials, and commercial preparations for TERN-701, a BCR-ABL inhibitor for CML. The offering is subject to market conditions and SEC registration.
2025-12-09 11:12
Terns Pharma Presents Updated And Expanded Data From Ongoing CARDINAL Trial Of TERN-701 In Patients With Previously Treated CML At ASH Annual Meeting And Exposition
64% MMR achievement by 24 weeks across all efficacy evaluable patients 75% MMR achievement by 24 weeks in efficacy evaluable patients at doses >320mg QDEncouraging safety/tolerability profile maintained with
2025-12-09 03:53
